Business Wire

Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, Chugai) and Eli Lilly and Company (NYSE: LLY, Lilly) today announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005486/en/

Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833. Chugai will receive an upfront payment of $50 million and is eligible for milestone payments based on achievement of certain predetermined milestones. If the molecule is successfully commercialized, Chugai would also be eligible for royalty payments.

“As a global leader in diabetes care, Lilly is committed to developing the next generation of diabetes therapies,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific Officer and President of Lilly Research Laboratories. “This exciting new opportunity from Chugai could represent a significant step forward for improving outcomes for people with diabetes.”

“We are very pleased to announce the license agreement of OWL833 with Lilly, a world-leading company in diabetes care,” said Yasushi Ito, M.D., Ph.D., Chugai’s Executive Vice President, Co-head of Project & Lifecycle Management Unit. “We believe OWL833 can be a best-in-class oral non-peptide GLP-1 receptor agonist and that its value will be further enhanced through Lilly’s clinical development to contribute to people around the world who live with diabetes.”

There will be no change to Chugai's consolidated financials forecast for the fiscal year ending December 2018 as a result of this transaction.

This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly's 2018 non-GAAP earnings per share guidance as a result of this transaction.

This transaction is subject to potential competition authority clearances and other customary closing conditions.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.

In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.

The consolidated revenue in 2017 of Chugai totaled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).

Additional information is available on the internet at https://www.chugai-pharm.co.jp/english/.

About Lilly Diabetes

Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes and on Facebook: LillyDiabetesUS.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.

Lilly Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's licensing of Chugai’s investigational medicine, OWL833. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in implementing the transaction and in drug development. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the transaction, that the molecule will be approved on the anticipated timeline or at all, or that the potential product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Contact information

Chugai
For Media
Media Relations Group, Corporate Communications Dept., Chugai Pharmaceutical Co., Ltd.
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For Investors
Investor Relations Group, Corporate Communications Dept., Chugai Pharmaceutical Co., Ltd.
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
***
Lilly
Lilly Media
Scott MacGregor
Tel: +317-440-4699
E-mail: jsmacgregor@lilly.com
***
Lilly investors
Kevin Hern
Tel: +317-277-1838
E-mail: hern_kevin_r@lilly.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Survey Finds Fragmented Processes and System Silos Slowing Clinical Trials19.6.2019 11:19:00 CESTPressemelding

There is an industrywide drive to streamline trial processes and systems for better study visibility and collaboration, according to the Veeva 2019 Unified Clinical Operations Survey, one of the largest-ever surveys of clinical operations professionals. New research from Veeva Systems (NYSE:VEEV) finds that all (100%) respondents surveyed report the need to improve information exchange among study partners. On average, they utilize at least three methods to share trial data and documents among sponsors, CROs, and sites, with email as the primary tool. Majorities say the move to streamline information exchange is driven by the need to reduce manual processes (71%), improve collaboration (66%), and increase visibility and oversight (64%) during trials. Nearly all sponsors and CROs (99%) say they also need to unify clinical applications for greater visibility (70%) and easier collaboration (61%). Many of the challenges in managing trials stem from siloed processes and systems that prevent

Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady19.6.2019 11:00:00 CESTPressemelding

Virgin Voyages is upping the game for its top suites aboard the highly anticipated Scarlet Lady, with new offerings to ensure that Mega RockStars won’t have to worry about a thing during their voyage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005107/en/ Geri Horner of the Spice Girls testing out Virgin Voyages Mega Rockstar Suites in New Video (Photo: Business Wire) Geri Horner Test Drives RockStar Suites In celebration of the expanded offerings, the brand has today released exclusive video content of the suites, which features Virgin Group founder, Sir Richard Branson, and legendary British pop star, Geri Horner, of the hugely successful girl group, the Spice Girls. The video documents Horner test driving the Virgin Voyages ‘Gorgeous Suite,’ one of the ship’s most glamorous cabins, as a favor to her longtime friend, Branson. Following Horner’s journey through the suite, the footage chronicles her full RockStar ex

beqom Study Shows U.S., UK Employees Aware of Gender Wage Gaps but Not of Actions Taken by Employers or Governments to Close Them19.6.2019 11:00:00 CESTPressemelding

Despite three in four workers (75%) saying they are aware of gender pay gaps existing in their country, nearly one in five (19%) admit they are not aware. More U.S. workers (21%) are unaware of gender pay gaps than UK workers (17%); among age groups, Millennials (24%) are the most unaware, compared to 16% of Gen Zs and 11% of Baby Boomers. These findings are according to beqom’s The Gender Pay Gap: What Your Employees Really Think report, which assesses enterprise worker perception on progress made in the last year to improve the gender pay gap in the U.S. and UK and aims to uncover employee perceptions about pay and identify areas for improvement. When it comes to preventing or closing pay gaps, employees believe the U.S. significantly trails the UK, with nearly one-third of UK workers (32%) saying their employer has announced a commitment to solve the pay gap compared to 13% of U.S. workers. Additionally, more UK workers (18%) say their employer has adjusted salaries for female emplo

Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 10:05:00 CESTPressemelding

Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA19.6.2019 10:00:00 CESTPressemelding

Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005222/en/ Invivoscribe Headquarters - San Diego, CA (Photo: Business Wire) The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival (OS) compared to salvage chemotherapy when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay. Mutations in the FLT3 gene are among the most important driver mutations in AML. This milestone furt

BearingPoint Acquires Public Services Consultancy Prederi in the UK19.6.2019 08:50:00 CESTPressemelding

Management and technology consultancy BearingPoint made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. The acquisition supports BearingPoint’s overall growth objectives, strengthens its presence in the UK, and broadens its public service capabilities. With this transaction, two highly profitable companies join forces. Prederi provides expert advice and consultancy and serves a large number of prestigious UK public sector clients. For many years, Prederi has been generating stable revenue streams. The Prederi team now expands BearingPoint’s expertise and capabilities in one of the largest and most competitive public services markets in Europe. “With the acquisition of Prederi we are continuing our growth strategy in selected markets with consultancies that are highly focused and strongly differentiated,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Prederi's portfolio is a perfect complement to our public service strategy